29 March 2024 – EMA has advised the granting of marketing authorization within the European Union (EU) for Emblaveo (aztreonam-avibactam), intended for managing complex intra-abdominal and urinary tract infections, hospital-acquired pneumonia, and infections provoked by specific strains of bacteria (aerobic Gram-negative) in cases where treatment choices are scarce.

Infections caused by Gram-negative bacteria that demonstrate resistance to numerous existing antibiotics pose a significant public health concern, as patients are often left with limited or even no treatment alternatives. It's estimated that infections stemming from multidrug-resistant bacteria result in approximately 35,000 fatalities annually within the EU.

For more information, see here.